Integrated risk assessment of a hydroxyapatite-protein-composite for use in oral care products: A weight-of-evidence case study

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 2, 2011, Pages 310-323

  Scheel, Julia ^a   Hermann, Martina ^a  

^a HENKEL KGAA   (Germany)

Author keywords

Biocomposite; Hydroxyapatite; Particles; Risk assessment; Weight of evidence

Indexed keywords

BIOMEDICAL AND DENTAL MATERIALS; GELATIN; HYDROXYAPATITE PROTEIN COMPOSITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CELL ASSAY; CELL STRAIN 3T3; CHORIOALLANTOIS; COMPOSITE MATERIAL; CONTROLLED STUDY; CYTOTOXICITY TEST; HAZARD ASSESSMENT; HUMAN; HUMAN CELL; HYGIENE PRODUCT; IN VITRO STUDY; MOUSE; MOUTH HYGIENE; NONHUMAN; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PRODUCT SAFETY; RAT; RISK ASSESSMENT; SCREENING TEST; TOXICITY TESTING;

ACRYLIC RESINS; ANIMALS; BALB 3T3 CELLS; CHICK EMBRYO; COMPOSITE RESINS; CONSUMER PRODUCT SAFETY; COSMETICS; DURAPATITE; GELATIN; HUMANS; MICE; POLYURETHANES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RISK ASSESSMENT; TOOTHPASTES;

ANIMALIA; MAMMALIA;

EID: 79952068552     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.11.003     Document Type: Article

References (90)

1. Aam B.B., Fonnum F. Carbon black particles increase reactive oxygen species formation in rat alveolar macrophages in vitro. Arch. Toxicol. 2007, 81:441-446.
2. Addy M. Dentine hypersensitivity: new perspectives on an old problem. Int. Dent. J. 2002, 52:367-375.
3. Aframian D.J., et al. The distribution of oral mucosal pH values in healthy saliva secretors. Oral Dis. 2006, 12:420-423.
4. Albrecht C., et al. Surface-dependent quartz uptake by macrophages: potential role in pulmonary inflammation and lung clearance. Inhal. Toxicol. 2007, 19(Suppl. 1):39-48.
5. Albrecht C., et al. Evaluation of cytotoxic effects and oxidative stress with hydroxyapatite dispersions of different physicochemical properties in rat NR8383 cells and primary macrophages. Toxicol. In Vitro 2009, 23:520-530.
6. Araujo J., et al. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf. B Biointerfaces 2009, 72:48-56.
7. Arts C.J.J., et al. The use of a bioresorbable nano-crystalline hydroxyapatite paste in acetabular bone impaction grafting. Biomaterials 2006, 27:1110-1118.
8. Balduzzi M., et al. In vitro effects on macrophages induced by noncytotoxic doses of silica particles possibly relevant to ambient exposure. Environ. Res. 2004, 96:62-71.
9. Bardow A., et al. Saliva. Clinical Oral Physiology 2004, Quintessence, Copenhagen, pp. 17-18, 30-33. T.S. Miles (Ed.).
10. Bloebaum R.D., et al. Dissolution of particulate hydroxyapatite in a macrophage organelle model. J. Biomed. Mater. Res. 1998, 40:104-114.
11. Borm P.J., et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol. 2006, 3:11.
12. Bridges J.W., Bridges O. Integrated risk assessment and endocrine disrupters. Toxicology 2004, 205:11-15.
13. Brown D.M., et al. Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol. Appl. Pharmacol. 2001, 175:191-199.
14. Busso M. Calcium hydroxylapatite (Radiesse): safety, techniques and pain reduction. J. Drugs Dermatol. 2009, 8:s21-s23.
15. Cui F.Z., et al. Biodegradation of a nano-hydroxyapatite/collagen composite by peritoneal monocyte macrophages. Cells Mater. 1996, 6:31-44.
16. Del Fabbro M., et al. Fluid dynamics of gingival tissues. J. Periodontal Res. 1998, 33:328-334.
17. Donaldson K., et al. Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol. 2005, 2:10.
18. EC, 1976. Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. OJ L 262, 27.7.1976. Directive as last amended by Commission Directive 2002/34/EC (OJ L 102, 18.4.2002, p. 19). 169 ff.
19. EC, 2003. Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. OJ L 66, 11.3.2003. 26 ff.
20. ECETOC, Workshop on Testing Strategies to Establish the Safety of Nanomaterials. 7-8 November 2005, Barcelona, Workshop Report No. 7, 2006.
21. ECHA, Guidance on information requirements and chemical safety assessment, 2007. p. 182.
22. Ericsson Y. Enamel apatite solubility. Acta Odont. Scand. 1949, 8:60-71.
23. Eskes C., et al. Eye irritation. Altern. Lab. Anim. 2005, 33(Suppl. 1):47-81.
24. EU, Guidance to Regulation (EC) No 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures, ECHA Reference: ECHA-09-G-02-EN, 2009.
25. Evans E.J. Toxicity of hydroxyapatite in vitro: the effect of particle size. Biomaterials 1991, 12:574-576.
26. Fjaertoft M., et al. Micropuncture measurements of interstitial fluid pressure in normal and inflamed gingiva in rats. J. Periodontal Res. 1992, 27:534-538.
27. Grandjean-Laquerriere A., et al. Importance of the surface area ratio on cytokines production by human monocytes in vitro induced by various hydroxyapatite particles. Biomaterials 2005, 26:2361-2369.
28. Grandjean-Laquerriere A., et al. The effect of the physical characteristics of hydroxyapatite particles on human monocytes IL-18 production in vitro. Biomaterials 2004, 25:5921-5927.
29. Guo X., et al. Biocompatibility of self-designed absorbable hydroxyapatite/poly (dl-lactide) composites. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 1999, 16:135-139.
30. Gupta H., et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2009, 6:324-333.
31. Hall B., et al. European consumer exposure to cosmetic products, a framework for conducting population exposure assessments. Food Chem. Toxicol. 2007, 45:2097-2108.
32. Henkel, 2005. Small particles with great potential. Press release Henkel GmbH & Co. KGaA. http://www.henkel.com/cps/rde/xchg/SID-0AC8330A-4805D2D5/henkel_com/hs.xsl/12028_5860_COE_HTML.htm.
33. Heraeus Kulzer GmbH, 2005. Ostim, Product Information; Scientific Information. http://www.ostim-dental.de.
34. Hirvonen M.R., et al. Heat shock proteins and macrophage resistance to the toxic effects of nitric oxide. Biochem. J. 1996, 315(Pt. 3):845-849.
35. Holsapple M.P., et al. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs. Toxicol. Sci. 2005, 88:12-17.
36. Huang J., et al. In vitro assessment of the biological response to nano-sized hydroxyapatite. J. Mater. Sci. Mater. Med. 2004, 15:441-445.
37. Huber F.X., et al. First histological observations on the incorporation of a novel nanocrystalline hydroxyapatite paste OSTIM in human cancellous bone. BMC Musculoskelet. Disord. 2006, 7:50.
38. Huber F.X., et al. Evaluation of a novel nanocrystalline hydroxyapatite paste and a solid hydroxyapatite ceramic for the treatment of critical size bone defects (CSD) in rabbits. J. Mater. Sci. Mater. Med. 2007, 9:33-38.
39. Huber F.X., et al. Open reduction and palmar plate-osteosynthesis in combination with a nanocrystalline hydroxyapatite spacer in the treatment of comminuted fractures of the distal radius. J. Hand Surg. [Br] 2006, 31:298-303.
40. Huber F.X., et al. The use of nanocrystalline hydroxyapatite for the reconstruction of calcaneal fractures: preliminary results. J. Foot Ankle Surg. 2006, 45:322-328.
41. Huber F.X., et al. Void filling of tibia compression fracture zones using a novel resorbable nanocrystalline hydroxyapatite paste in combination with a hydroxyapatite ceramic core: first clinical results. Arch. Orthop. Trauma Surg. 2006, 126:533-540.
42. Jantova S., et al. In vitro effects of fluor-hydroxyapatite, fluorapatite and hydroxyapatite on colony formation, DNA damage and mutagenicity. Mutat. Res. 2008, 652:139-144.
43. Kannan T.P., et al. Chromosome aberration test for hydroxyapatite in sheep. Med. J. Malaysia 2004, 59(Suppl. B):168-169.
44. Kannan T.P., et al. In vivo chromosome aberration test for hydroxyapetite in mice. Med. J. Malaysia 2004, 59(Suppl. B):115-116.
45. Kilian O., et al. Einfluss von Ostim kombiniert mit autologen thrombozytären Wachstumsfaktoren auf die Knochendefektheilung in vivo. Biomaterialien 2002, 3:70-73.
46. Kumta P.N., et al. Nanostructured calcium phosphates for biomedical applications: novel synthesis and characterization. Acta Biomater. 2005, 1:65-83.
47. Landi E., et al. Biomimetic Mg-substituted hydroxyapatite: from synthesis to in vivo behaviour. J. Mater. Sci. Mater. Med. 2008, 19:239-247.
48. Laquerriere P., et al. Importance of hydroxyapatite particles characteristics on cytokines production by human monocytes in vitro. Biomaterials 2003, 24:2739-2747.
49. Larsen M.J., Pearce E.I. A computer program for correlating dental plaque pH values, cH+, plaque titration, critical pH, resting pH and the solubility of enamel apatite. Arch. Oral Biol. 1997, 42:475-480.
50. Laschke M.W., et al. Injectable nanocrystalline hydroxyapatite paste for bone substitution: in vivo analysis of biocompatibility and vascularization. J. Biomed. Mater. Res. B Appl. Biomater. 2007, 82:494-505.
51. Lewinski N., et al. Cytotoxicity of nanoparticles. Small 2008, 4:26-49.
52. Li H., et al. Preparation and biological safety evaluation of porous n-HA/PA66 composite. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008, 25:1126-1129.
53. Liu C., et al. Evaluation of the biocompatibility of a nonceramic hydroxyapatite. J. Endod. 1997, 23:490-493.
54. Mayhew T.M., et al. A review of recent methods for efficiently quantifying immunogold and other nanoparticles using TEM sections through cells, tissues and organs. Ann. Anat. 2009, 191:153-170.
55. McNamee P., et al. A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: eye irritation. Regul. Toxicol. Pharmacol. 2009, 54:197-209.
56. Merck, Sicherheitsdatenblatt, Hydroxylapatit für die Biochromatographie (15μm) (0-30μm) Art. 105199, 2000.
57. Mitschik S., et al. Effects of particulate matter on cytokine production in vitro: a comparative analysis of published studies. Inhal. Toxicol. 2008, 20:399-414.
58. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
59. Motskin M., et al. Hydroxyapatite nano and microparticles: correlation of particle properties with cytotoxicity and biostability. Biomaterials 2009, 30:3307-3317.
60. Palmer L.C., et al. Biomimetic systems for hydroxyapatite mineralization inspired by bone and enamel. Chem. Rev. 2008, 108:4754-4783.
61. Pankratov A.S., et al. The immunotropic and allergenic activity of hydroxyapatite with an ultrahigh degree of dispersion. Stomatologiia (Mosk) 1994, 73:37-40.
62. Pardeike J., Muller R.H. Dermal and ocular safety of the new phospholipase A2 inhibitors PX-18 and PX-13 formulated as drug nanosuspension. J. Biomed. Nanotechnol. 2009, 5:437-444.
63. Rajab N.F., et al. DNA damage evaluation of hydroxyapatite on fibroblast cell L929 using the single cell gel electrophoresis assay. Med. J. Malaysia 2004, 59(Suppl. B):170-171.
64. Rauschmann M.A., et al. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections. Biomaterials 2005, 26:2677-2684.
65. Rudin, V.N. et al., 1994. Preparation of "Ostim Apatite" for stimulating growth in bone tissue. European Patent Application No. 0 664 133 A1.
66. Rumpel E., et al. The biodegradation of hydroxyapatite bone graft substitutes in vivo. Folia Morphol. (Warsz) 2006, 65:43-48.
67. Sauerwein, 2000. Zahnerhaltungskunde. Thieme, Stuttgart.
68. Sayes C.M., et al. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci. 2007, 97:163-180.
69. SCCP, The SCCP's (Scientific Committee on Consumer Products) Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation. 6th Revision, 2006.
70. Scheel J., et al. Exposure of the murine RAW 264.7 macrophage cell line to hydroxyapatite dispersions of various composition and morphology: assessment of cytotoxicity, activation and stress response. Toxicol. In Vitro 2009, 23:531-538.
71. Schmid O., et al. Dosimetry and toxicology of inhaled ultrafine particles. Biomarkers 2009, 14(Suppl. 1):67-73.
72. Schroeder, H.E., 2000. Orale Strukturbiologie. ISBN 3-13-540905-8.
73. Schweikl H., Schmalz G. Toxicity parameters for cytotoxicity testing of dental materials in two different mammalian cell lines. Eur. J. Oral Sci. 1996, 104:292-299.
74. Shamsuria O., et al. In vitro cytotoxicity evaluation of biomaterials on human osteoblast cells CRL-1543; hydroxyapatite, natural coral and polyhydroxybutarate. Med. J. Malaysia 2004, 59(Suppl. B):174-175.
75. Steiling W., et al. The HET-CAM, a useful in vitro assay for assessing the eye irritation properties of cosmetic formulations and ingredients. Toxicol. In Vitro 1999, 13:375-384.
76. Suzina A.H., et al. Mutagenicity of CORAGRAF and REKAGRAF in the Ames test. Med. J. Malaysia 2004, 59(Suppl. B):105-106.
77. Takamura K., et al. Evaluation of carcinogenicity and chronic toxicity associated with orthopedic implants in mice. J. Biomed. Mater. Res. 1994, 28:583-589.
78. Thorwarth W.M., et al. Untersuchung zur knöchernen Regeneration ossärer Defekte unter Anwendung eines nanopartikulären Hydroxylapatits (Ostim). Implantologie 2004, 12:21-32.
79. Torrado A., et al. Cytotoxicity of a new toothpaste based on an ion exchange resin mixture. Am. J. Dent. 2005, 18:267-269.
80. Trofimov V.V., et al. A biological compatibility study of hydroxyapatite. Stomatologiia (Mosk) 1996, 75:20-22.
81. Ulstrup A.K., Hartzen S.H. Leptotrichia buccalis: a rare cause of bacteraemia in non-neutropenic patients. Scand. J. Infect. Dis. 2006, 38:712-716.
82. Unfried K., et al. Cellular responses to nanoparticles: target structures and mechanisms. Nanotoxicology 2007, 1:52-71.
83. Wahl D.A., Czernuszka J.T. Collagen-hydroxyapatite composites for hard tissue repair. Eur. Cell Mater. 2006, 11:43-56.
84. Webster T.J., Ahn E.S. Nanostructured biomaterials for tissue engineering bone. Adv. Biochem. Eng. Biotechnol. 2007, 103:275-308.
85. Weed D.L. Weight of evidence: a review of concept and methods. Risk Anal. 2005, 25:1545-1557.
86. Wenisch S., et al. In vivo mechanisms of hydroxyapatite ceramic degradation by osteoclasts: fine structural microscopy. J. Biomed. Mater. Res. A 2003, 67:713-718.
87. Werner U. In Situ Gelling Nasal Inserts for Prolonged Drug Delivery. Fachbereich Biologie, Chemie, Pharmazie 2003, Freie Universität Berlin, Berlin.
88. Wolf N.B., et al. Influences of opioids and nanoparticles on in vitro wound healing models. Eur. J. Pharm. Biopharm. 2009, 73:34-42.
89. Yamada T. Textbook of Gastroenterology 1999, Lippincott Williams & Wilkins.
90. Ye L., et al. Genotoxicity of a new NanoHA-PA66 root filling material in vitro. Hua Xi Kou Qiang Yi Xue Za Zhi 2004, 22:93-95.